- Description
- Details
- Subprojects
- History
- Relations
- Publications
| Project Title: | Can rapamycin retard age-related diseases? | |
| Principal Investigators (PI): |
RICHARDSON ARLAN G
|
|
| Project Number: | 5RC2AG036613-02 | |
| Organization: | UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT | |
| Project Description: | ||
|---|---|---|
| The recent report that rapamycin increases the lifespan of mice is a major breakthrough in aging because it can be translated easily to humans. However, the critical question is whether long-term rapamycin treatment improves healthspan/quality-of-life as well as lifespan. This question must be addressed because of rapamycin's potential negative effects on the immune system. The "GO" grant application presented here is a unique, large, multi-investigator study designed to answer the following questions: (1) Does rapamycin retard/reduce age-related diseases [e.g., cancer, neurodegeneration, atherosclerosis, and nephropathy]? (2) Do mice given rapamycin maintain a better/longer healthspan (e.g., sensitivity of mice to infectious agents, autoimmunity, and biological function)? (3) Does rapamycin improve pathways that impact healthspan (e.g., autophagy and inflammation)? The data generated by this grant will be extremely important to the NIH's mission of improving health because it will provide the first information on how rapamycin-treatment, which increases lifespan, affects the healthspan of mice. The unique "GO" grant mechanism allows us to bring together 21 investigators (with expertise in a variety of areas of aging research) in 9 Projects and 3 Cores to conduct a 2-year comprehensive assessment of rapamycin's effect on the health status of mice. Such a multi-investigator effort is necessary because healthspan is poorly defined and encompasses multiple functions, which potentially interact. It took 2 decades of research funded through "normal" NIH-mechanisms to establish that caloric restriction increased the healthspan of rodents, i.e., the current data show that caloric restriction retards/reduces age-related diseases and improves physiological functions that decline with age. Within 2 years, the data generated by this grant will provide a similar, if not better, assessment of the effect of rapamycin on healthspan. The environment at San Antonio is ideal for conducting such a comprehensive study because of the outstanding animal resources and pathological expertise in the San Antonio Nathan Shock Aging Center, the large number of investigators with expertise in aging (especially using mice to study aging), and our investigators'first-hand experience in feeding rapamycin to mice and measuring rapamycin levels in the diet and blood of mice. We believe that our study meets the goals of the "GO" grants because of the unique nature of the question studied and because the data generated have the potential to immediately stimulate translational research into the effectiveness of rapamycin in treating various age-related diseases in humans. In addition, this application fulfills the goal of the American Recovery and Reinvestment Act of 2009, to provide immediate stimulus to the economy by increasing employment opportunities. For example, funds requested in this application will provide salary support for 23 new positions for technicians/post-doctoral fellows for 2 years and more than 50% of the per diem costs will go for the salaries of new personnel caring for the mice. PUBLIC HEALTH RELEVANCE: The outcomes from this grant will be extremely important to the NIH's mission of improving health because it will provide the first information on the long-term effect of rapamycin on healthspan and the efficacy of using rapamycin to treat a broad range of age-related diseases relevant to humans. | ||
| Project Terms: | ||
| Address Affect Age Aging American Applications Grants Area Atheroscleroses Atherosclerosis Atherosclerotic Cardiovascular Disease Autoimmune Status Autoimmunity Autophagocytosis Award Biological Function Biological Process Blood Caloric Restriction Cancers Caring Cell Communication and Signaling Cell Signaling Circulatory Collapse Communities DNA Alteration DNA mutation Data Diet Disease Disorder Effectiveness Effects, Longterm Employment Opportunities Environment FDA approved Female Foundations Funding Funding Mechanisms Gene Alteration Gene Mutation Genetic mutation Goals Grant Grant Proposals Grants, Applications Hand Health Health Status Human Human Resources Human, General Huntington Chorea Huntington Disease Huntington's Huntington's Disease Huntington's Disease Pathway Huntingtons Disease INFLM Immune system Immunosuppressants Immunosuppressive Agents Infectious Agent Inflammation Intervention Intervention Strategies Intracellular Communication and Signaling Invertebrata Invertebrates Invertebrates, General Investigators Kidney Diseases Length of Life Level of Health Life Long-Term Effects Longevity Malignant Neoplasms Malignant Tumor Mammalia Mammals Mammals, General Mammals, Mice Mammals, Rodents Man (Taxonomy) Man, Modern Manpower Measures Method LOINC Axis 6 Methodology Methods Mice Microencapsulations Mission Murine Mus NIH National Institutes of Health National Institutes of Health (U.S.) Nature Nephropathy Nerve Degeneration Neuron Degeneration Outcome Pathology Pathway interactions Physiologic Physiological Play Position Positioning Attribute Postdoc Postdoctoral Fellow Procedures Programs (PT) Programs [Publication Type] Progressive Chorea, Hereditary, Chronic (Huntington) QOL Quality of life RAFT-1 gene product Rapamune Rapamycin Recovery Renal Disease Reporting Research Research Associate Research Design Research Personnel Researchers Reticuloendothelial System, Blood Rodent Rodentia Rodentias Role Salaries Senescence Sequence Alteration Shock Signal Transduction Signal Transduction Systems Signaling Sirolimus Site Stimulus Study Type Testing Translating Translatings Translational Research Translational Research Enterprise Translational Science United States United States National Institutes of Health Wages Yeasts age dependent age related animal resource anti aging anti aging drug anti aging medicine antiaging antiaging drug antiaging medicine atheromatosis atherosclerotic vascular disease autophagy biological signal transduction body system, allergic/immunologic calorie restriction circulatory shock cost disease/disorder experience feeding immunosuppressive improved infectious organism interventional strategy kidney disorder language translation life span lifespan mTOR gene product mTOR protein male malignancy mammalian target of rapamycin (mTOR) meetings mouse model neoplasm/cancer neural degeneration neurodegeneration neuronal degeneration organ system, allergic/immunologic pathway personnel post-doc post-doctoral programs public health relevance renal disorder self recognition (immune) senescent social role study design translation research enterprise | ||
| Project Title: | Can rapamycin retard age-related diseases? | |
| Principal Investigators (PI): |
RICHARDSON ARLAN G
|
|
| Project Number: | 5RC2AG036613-02 | |
| Organization: | UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT | |
| Project Categories: | ||
|---|---|---|
|
• Natural Sciences |
||
| Other Information: | ||
| Fiscal Year: | 2009 | |
| Project Start Date: | 30 September 2009 | |
| Project End Date: | 31 August 2011 | Administering Institute Or Center: | AG |
| Project Funding Information: | ||
| Total Funding: | $2,650,628 | |
| Year | Funding Organization | Total Funding, $ |
|---|---|---|
| 2010 | NATIONAL INSTITUTE ON AGING | $2,650,628 |
| Project Title: | Can rapamycin retard age-related diseases? | ||
| Principal Investigators (PI): |
RICHARDSON ARLAN G
|
||
| Project Number: | 5RC2AG036613-02 | ||
| Organization: | UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT | ||
| Project_number | Title | Year | FY Total Cost |
|---|---|---|---|
| There are no results for this project in database. | |||
| Project Title: | Can rapamycin retard age-related diseases? | ||
| Principal Investigators (PI): |
RICHARDSON ARLAN G
|
||
| Project Number: | 5RC2AG036613-02 | ||
| Organization: | UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT | ||
| Project number | Project title | Principal investigator | |
|---|---|---|---|
| There are no any related projects. | |||
| Project Title: | Can rapamycin retard age-related diseases? | |||
| Principal Investigators (PI): |
RICHARDSON ARLAN G
|
|||
| Project Number: | 5RC2AG036613-02 | |||
| Organization: | UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT | |||
| Title | Abstract | Authors | Year | Rel |
|---|
